Navigation Links
Neurologix Announces Publication of Landmark Gene Therapy Study,Demonstrating Safety and Statistically Significant Improvement in,Patients With Advanced Parkinson's Disease

e Company will be able to successfully receive permission from the FDA to begin a Phase I safety trial for treatment of epilepsy.

Other factors and assumptions not identified above could also cause the actual results to differ materially from those set forth in the forward-looking statements. Additional information regarding factors that could cause results to differ materially from management's expectations is found in the section entitled "Risk Factors" in the Company's 2006 Annual Report on Form 10-KSB. Although the Company believes these assumptions are reasonable, no assurance can be given that they will prove correct. Accordingly, you should not rely upon forward-looking statements as a prediction of actual results. Further, the Company undertakes no obligation to update forward-looking statements after the date they are made or to conform the statements to actual results or changes in the Company's expectations.

Contact

Neurologix, Inc.
Marc Panoff, CFO, 201-592-6451 (Investors)
marcpanoff@neurologix.net
or
Kureczka/Martin Associates
Joan Kureczka, 415-821-2413 (Media)
Jkureczka@comcast.net


'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Neurologix to Present at the Third Annual C.E. Unterberg Towbin Emerging Growth Conference
2. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
Post Your Comments:
(Date:1/23/2015)... , Jan. 23, 2015 More than a third ... quarter of those with private insurance, filled a prescription for ... a report in this week,s Morbidity and Mortality Weekly Report ... care providers to treat moderate to severe pain.  They are ...
(Date:1/23/2015)... MERIDIAN, Idaho , Jan. 23, 2015  Now available ... Patent No. 7,849,611) support that prevents ankle sprains by ... a brace, it fits securely around the outside of ... ankle mobility & comfort while still offering protection against ...
(Date:1/23/2015)... 2015  CytoSorbents Corporation (NASDAQ CM: CTSO), a critical ... adsorber to reduce deadly inflammation in critically-ill and ... net of transaction costs, in non-dilutive funding as ... Certificate Transfer Program sponsored by the New Jersey ...
Breaking Medicine Technology:Opioid painkillers widely prescribed among reproductive age women 2Opioid painkillers widely prescribed among reproductive age women 3The Armor1 Ankle Roll Guard is the New Breakthrough Solution for Ankle Sprain Prevention! 2CytoSorbents Receives $385,000 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program 2CytoSorbents Receives $385,000 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program 3
(Date:1/22/2015)... Dallas, TX (PRWEB) January 22, 2015 ... the issue of experience and person-centeredness in the long-term ... moving towards action across the continuum. The paper, “The ... the Continuum,” engages perspectives and practices of the patient, ...
(Date:1/22/2015)... For over 20 years, Dr. David Cruz of ... area has treated just about every type of injury that ... And for those same twenty-plus years, the team at Doctors ... with the best possible doctor. With the combined breadth ...
(Date:1/22/2015)... New York, NY (PRWEB) January 22, 2015 ... American College of Sports Medicine flagship journal Medicine ... supplementation with L-Citrulline before exercise may help reduce ... strenuous exercise. 1 , Participants in the ...
(Date:1/22/2015)... IsoComforter, Inc. has introduced the most innovative ... design to treat specific body parts and muscle groups. , ... easy to use patented cold therapy machine with the innovative ... and muscle injuries. IsoComforter has become the industry leader ...
(Date:1/22/2015)... January 22, 2015 EBSCO Information Services ... are expanding their relationship in an effort to further promote ... world. While EBSCO has long made AMA journals available via ... agent for The JAMA Network. , Long known ...
Breaking Medicine News(10 mins):Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 3Health News:Industry Leading Chiropractor in Oceanside Joins the Doctors on Liens Network 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3Health News:IsoComforter Introduces Best of Class Cold Therapy Product to the Worldwide Market 2Health News:EBSCO Expands Partnership with the American Medical Association 2Health News:EBSCO Expands Partnership with the American Medical Association 3Health News:EBSCO Expands Partnership with the American Medical Association 4
... Cold Spring Harbor, NY -- A team of neuroscientists at ... UC San Diego (UCSD) has collected evidence suggesting that a ... locus of human depression. In two rat ... in a tiny area in the central brain called the ...
... HealthDay Reporter , WEDNESDAY, Feb. 23 (HealthDay ... pain -- an increasingly controversial treatment that has exploded ... to higher rates of permanent disability for worker,s compensation ... finds. Researchers randomly selected 725 people with low ...
... By Amanda Gardner HealthDay Reporter , TUESDAY, Feb. ... the areas of your brain closest to the phone,s antenna, ... effects pose any long-term health risk. "We don,t know ... potential beneficial effects. We don,t know one way or the ...
... a rock concert, noise-induced hearing loss is one of the ... School of Medicine in St. Louis have identified a low-dose, ... before they are exposed to loud noise. The drugs, already ... exposure. While both drugs are known to protect hearing ...
... San Francisco, CA February 22, 2011 The ... million in research grants as part of its Mobilizing ... populations with chronic diseases through the use of mobile-phone ... $250,000 each, will support studies on diabetes care and ...
... News) -- Moderate alcohol consumption may help protect against heart ... One team at the University of Calgary reviewed 84 ... that people who drink alcohol in moderation (one drink or ... likely to develop heart disease as those who don,t drink ...
Cached Medicine News:Health News:Neuroscientists find overlooked brain area is an important locus of depression 2Health News:Neuroscientists find overlooked brain area is an important locus of depression 3Health News:Spinal Fusion Surgery May Leave Some Back Pain Patients Worse Off: Study 2Health News:Spinal Fusion Surgery May Leave Some Back Pain Patients Worse Off: Study 3Health News:Cell Phones Affect Areas of the Brain, Study Shows 2Health News:Cell Phones Affect Areas of the Brain, Study Shows 3Health News:2 drugs protect hearing better than 1 2Health News:McKesson Foundation awards $1.3 million in 6 Mobilizing for Health Research grants 2Health News:More Evidence Ties Moderate Drinking to Heart Health 2
Custom programming of 3 hot blocks and 1 cold block, 30% reduction in cycling time, Unmatched well-to-well uniformity, No gradient feature...
... is the first instrument engineered to match ... rapid temperature cycling system is based on ... contained in microcapillary tubes or thin walled ... with blasts of high velocity air results ...
... Excellent performance, small footprint, simple intuitive programming ... Primus 25 the ideal personal cycler in ... flexiblock design and the self-adjusting heated lid ... 13x 0.5ml vessels or a microplate of ...
... Ideal for day-to-day ... uniformity of 0.1C ,30% ... over Peltier or coolant-based ... eliminate temperature ramping ,Options ...
Medicine Products: